WyoVentures will allow University of Wyoming to manage VC funds while also acting as a conduit to startups from the local ecosystem.

DesertDx has spun out of UA's Tech Launch Arizona to commercialise a comprehensive single blood-draw diagnostics test for lung cancer.

AIG-backed cancer and genetic disease developer BridgeBio Pharma has filed for a $225m initial public offering on the Nasdaq Global Market.

The genetic drug developer is targeting up to $86m in an IPO that would enable Alexandria Venture Investments to score an exit.

Existing backer Google has reinvested in the mobile operating system developer to increase its overall funding to $79m.

Aurora has announced it is set to buy the lidar system developer, which had raised more than $21m from investors including BMW i Ventures and Toyota AI Ventures.

Ideaya priced its shares below their range to raise $50m, providing exits for Alphabet, WuXi AppTec, Celgene, Roche and Novartis.

GuideWell Mutual, Blue Shield California and existing backer Premera Blue Cross all invested in the healthcare prediction platform developer based on Stanford research.

Mars has partnered Jerusalem Venture Partners in a venture that will involve them investing in Israel-based developers of food, agriculture and nutrition technologies.

The T-Cell therapy developer, based on research at Baylor College of Medicine, has received funding in a Gilead Sciences-backed series B round led by Fidelity Management and Research.